Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections

Ming Tsung Lin; Yeh Pin Chou; Tsung Hui Hu; Hsien Chung Yu; Yu Chun Hsu; Ming Chao Tsai; Po Lin Tseng; Kuo Chin Chang; Yi Hao Yen; King Wah Chiu

doi:10.1007/s00705-013-1786-4

Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections

Ming Tsung Lin
, Yeh Pin Chou
, Tsung Hui Hu^*
, Hsien Chung Yu
, Yu Chun Hsu
, Ming Chao Tsai
, Po Lin Tseng
, Kuo Chin Chang
, Yi Hao Yen
, King Wah Chiu

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

3 Scopus citations

Abstract

We evaluated second-line salvage therapy with adefovir + telbivudine (group 1), adefovir followed by adefovir + telbivudine (group 2), or lamivudine + adefovir followed by adefovir + telbivudine (group 3) in hepatitis B patients with an inadequate virologic response to lamivudine treatment. Simple linear regression analysis showed that for each additional month of treatment, the most significant reduction in viral load occurred in group 1 (HBV DNA [Log₁₀ IU/mL]: group 1, -0.149; group 2, -0.081; group 3, -0.123). Generalized estimating equation analysis revealed that compared to group 1, hepatitis B virus (HBV) DNA levels were 1.203 and 0.443 Log₁₀ IU/mL higher in groups 2 and 3, respectively. Overall, a significant reduction in viral load (-0.060 Log₁₀ IU/mL) was observed for each additional month of treatment. Adefovir + telbivudine treatment resulted in a significant reduction in HBV DNA levels. Moreover, telbivudine treatment resulted in a significant reduction in viral load (-0.050 Log₁₀ IU/mL) compared to lamivudine treatment after the emergence of lamivudine resistance.

Original language	English
Pages (from-to)	29-37
Number of pages	9
Journal	Archives of Virology
Volume	159
Issue number	1
DOIs	https://doi.org/10.1007/s00705-013-1786-4
State	Published - 01 2014
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00705-013-1786-4

Cite this

@article{c1e7f0f3f1f645b8a53efefb8d006289,

title = "Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections",

abstract = "We evaluated second-line salvage therapy with adefovir + telbivudine (group 1), adefovir followed by adefovir + telbivudine (group 2), or lamivudine + adefovir followed by adefovir + telbivudine (group 3) in hepatitis B patients with an inadequate virologic response to lamivudine treatment. Simple linear regression analysis showed that for each additional month of treatment, the most significant reduction in viral load occurred in group 1 (HBV DNA [Log10 IU/mL]: group 1, -0.149; group 2, -0.081; group 3, -0.123). Generalized estimating equation analysis revealed that compared to group 1, hepatitis B virus (HBV) DNA levels were 1.203 and 0.443 Log10 IU/mL higher in groups 2 and 3, respectively. Overall, a significant reduction in viral load (-0.060 Log10 IU/mL) was observed for each additional month of treatment. Adefovir + telbivudine treatment resulted in a significant reduction in HBV DNA levels. Moreover, telbivudine treatment resulted in a significant reduction in viral load (-0.050 Log10 IU/mL) compared to lamivudine treatment after the emergence of lamivudine resistance.",

author = "Lin, \{Ming Tsung\} and Chou, \{Yeh Pin\} and Hu, \{Tsung Hui\} and Yu, \{Hsien Chung\} and Hsu, \{Yu Chun\} and Tsai, \{Ming Chao\} and Tseng, \{Po Lin\} and Chang, \{Kuo Chin\} and Yen, \{Yi Hao\} and Chiu, \{King Wah\}",

year = "2014",

month = jan,

doi = "10.1007/s00705-013-1786-4",

language = "英语",

volume = "159",

pages = "29--37",

journal = "Archives of Virology",

issn = "0304-8608",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections

AU - Lin, Ming Tsung

AU - Chou, Yeh Pin

AU - Hu, Tsung Hui

AU - Yu, Hsien Chung

AU - Hsu, Yu Chun

AU - Tsai, Ming Chao

AU - Tseng, Po Lin

AU - Chang, Kuo Chin

AU - Yen, Yi Hao

AU - Chiu, King Wah

PY - 2014/1

Y1 - 2014/1

N2 - We evaluated second-line salvage therapy with adefovir + telbivudine (group 1), adefovir followed by adefovir + telbivudine (group 2), or lamivudine + adefovir followed by adefovir + telbivudine (group 3) in hepatitis B patients with an inadequate virologic response to lamivudine treatment. Simple linear regression analysis showed that for each additional month of treatment, the most significant reduction in viral load occurred in group 1 (HBV DNA [Log10 IU/mL]: group 1, -0.149; group 2, -0.081; group 3, -0.123). Generalized estimating equation analysis revealed that compared to group 1, hepatitis B virus (HBV) DNA levels were 1.203 and 0.443 Log10 IU/mL higher in groups 2 and 3, respectively. Overall, a significant reduction in viral load (-0.060 Log10 IU/mL) was observed for each additional month of treatment. Adefovir + telbivudine treatment resulted in a significant reduction in HBV DNA levels. Moreover, telbivudine treatment resulted in a significant reduction in viral load (-0.050 Log10 IU/mL) compared to lamivudine treatment after the emergence of lamivudine resistance.

AB - We evaluated second-line salvage therapy with adefovir + telbivudine (group 1), adefovir followed by adefovir + telbivudine (group 2), or lamivudine + adefovir followed by adefovir + telbivudine (group 3) in hepatitis B patients with an inadequate virologic response to lamivudine treatment. Simple linear regression analysis showed that for each additional month of treatment, the most significant reduction in viral load occurred in group 1 (HBV DNA [Log10 IU/mL]: group 1, -0.149; group 2, -0.081; group 3, -0.123). Generalized estimating equation analysis revealed that compared to group 1, hepatitis B virus (HBV) DNA levels were 1.203 and 0.443 Log10 IU/mL higher in groups 2 and 3, respectively. Overall, a significant reduction in viral load (-0.060 Log10 IU/mL) was observed for each additional month of treatment. Adefovir + telbivudine treatment resulted in a significant reduction in HBV DNA levels. Moreover, telbivudine treatment resulted in a significant reduction in viral load (-0.050 Log10 IU/mL) compared to lamivudine treatment after the emergence of lamivudine resistance.

UR - https://www.scopus.com/pages/publications/84893720366

U2 - 10.1007/s00705-013-1786-4

DO - 10.1007/s00705-013-1786-4

M3 - 文章

C2 - 23857507

AN - SCOPUS:84893720366

SN - 0304-8608

VL - 159

SP - 29

EP - 37

JO - Archives of Virology

JF - Archives of Virology

IS - 1

ER -

Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this